The Valley Desk

Clinical trial reportCancerPublished

Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names University of Pennsylvania. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer
Published
Subject terms
Humans; Ovarian Neoplasms; Neoplasm Recurrence, Local; Piperazines; Phthalazines; BRCA1 Protein; BRCA2 Protein; Prospective Studies; Mutation; Germ-Line Mutation; Adult; Aged
PubMed ID
39817648
PubMed Central ID
PMC11736996
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal